Trial Profile
A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular NHL (RV 0163).
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 30 Aug 2023 Planned End Date changed from 1 Feb 2024 to 1 Dec 2024.
- 30 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Apr 2024.
- 02 Feb 2023 Planned End Date changed from 1 Jul 2023 to 1 Feb 2024.